In particular monoclonal antibodies (mAbs) as nivolumab, pembrolizumab, atezolizumab, avelumab, and durvalumab directed to the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) immune checkpoint pathway proved significant efficacy as single arm, and represents a new therapeutic opportunity for many cancer patients. The gene discussed is CD274; the disease is cancer.